About Arcellx
Arcellx is a publicly listed company based in Gaithersburg (United States) founded in 2014 by David Hilbert, and was acquired by Gilead in February 2026. T cell-mediated therapies are developed for cancer and autoimmune diseases. It operates on a HealthTech model. Arcellx has raised $241.84 million across 6 funding rounds from investors including Gilead, LG and Takeda Pharmaceuticals. The company has 163 employees. Its chief executive, as recorded, is Rami Elghandour. Its website arcellx.com draws about 15 thousand monthly visits. Arcellx offers products and services including Cell Therapies and D-Domain Technology. Its focus areas include Biotechnology and Cancer Therapeutics. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Arcellx is engaged in the development of innovative cell therapies targeting cancer and autoimmune diseases. The company utilizes its proprietary D-Domain technology along with ddCAR and ARC-SparX platforms to enhance treatment approaches. Operating within the biotechnology sector, Arcellx aims to transform cancer treatment through scientific advancements and collaborative efforts. Its solutions are designed to prioritize patient care while challenging conventional methods in the fight against cancer.
- Headquarters Gaithersburg, United States
- Employees 163
- Founders David Hilbert
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website arcellx.com
- Social LinkedIn X
- Acquired by Gilead (Feb 2026)
- Legal Name Arcellx, Inc.
- Annual Revenue$107.94 M (USD)-2.16as on Dec 31, 2024
- Net Profit-$107.35 M (USD)-51.86as on Dec 31, 2024
- EBITDA-$132.38 M (USD)-50.71as on Dec 31, 2024
- Total Equity Funding$241.84M (USD)
in 6 rounds
- Latest Funding Round$100M (USD), Post-IPO
Feb 2023
- InvestorsGilead
& 23 more
- Employee Count163
- Acquired byGilead
(Feb 2026)
Products & Services of Arcellx
Arcellx offers a comprehensive portfolio of products and services, including Cell Therapies and D-Domain Technology.
Cell therapies are developed for cancer treatment solutions.
Innovative technology is used for advanced cell therapies.
Funding Insights of Arcellx
Arcellx has successfully raised a total of $241.84M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $241.84M
- Total Rounds 6
- Last Round Post-IPO — $100M
- Investors Count 23
All 6 funding rounds of Arcellx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $100M | Post-IPO | – | – | – |
| Feb 2022 | $10M | Post-IPO | – | – | – |
| Apr 2021 | $115M | Series C | – | Samsara BioCapital, CAM Capital | |
| Oct 2019 | $85M | Series B | – | Quan Capital, Solasta Ventures | |
| Aug 2019 | $41.84M | Series B | – | – | – |
| Sep 2017 | Seed | – | Novo Holdings | – |
24 investors in total: 24 institutional.
Investors in Arcellx
Arcellx has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, LG and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are directed toward early and growth stage companies. | quancapital.com | Pudong, China | ||
Investment in early-stage companies across AI, biotech, and cleantech sectors with access to global resources. | lgtechventures.com | |||
Venture capital investment firm | jvcmanagement.com | Northbrook, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| takedaventures.com | ||||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Venture capital firm focused on healthcare startups | solasta-ventures.com | Boston, United States | ||
Diversified investment, VC & financial advisory firm | 1974 | ajuib.co.kr | Seoul, South Korea | |
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States |
Investor details for Arcellx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arcellx
67 people are tracked at Arcellx (39 in leadership, 5 in board & advisors, 23 in team); the tracked headcount is 163.
| Name | Role | Group |
|---|---|---|
David Hilbert | Founder | Leadership |
Rami Elghandour | CEO | Leadership |
Shashi Kaithamana | VP, Protein Sciences | Leadership |
Heba Nowyhed | Chief Scientific Officer | Leadership |
Michelle Gilson | Chief Financial Officer | Leadership |
Neeraj Teotia | Chief Commercial Officer | Leadership |
Brad Gliner | VP, Clinical Research & Regulatory Affairs | Leadership |
Christopher Heery | Chief Medical Officer | Leadership |
Sowmya Mullapudi | Director, Market Access, Cell Therapy | Leadership |
Brian Murphy | VP, Cell Process Sciences | Leadership |
Aileen Fernandes | Chief Operating Officer | Leadership |
Doug Alleavitch | VP, Quality | Leadership |
Kate Aiken | Chief People Officer | Leadership |
Myesha Lacy | Chief Investor And Communications Officer | Leadership |
Jenny Mu | Director Of Translational Sciences | Leadership |
Narinder Singh | Chief Technical Officer | Leadership |
Margrit Rosado | Vice President, Value & Access | Leadership |
Pooja Balwani Pahwa | Marketing Director | Leadership |
Jie Ting | Senior Director, Cell Therapy RWE & HEOR | Leadership |
Tara Crnkovich | Head Of QA Operations | Leadership |
47 more people are available in the full profile.
Complete people profiles for Arcellx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Arcellx
Arcellx is a publicly listed company on the NASDAQ with ticker symbol ACLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Feb 2022
- Listed onNASDAQ: ACLX
- Listed entityArcellx, Inc.
- Exchange sectorHealth technology
- ISINUS03940C1009
- Share price$115.07 (+0.03% on the day) · 2026-04-29
- Market capitalisation$6.73B
- EPS (diluted, trailing year)$-4.05
- Volume (last session)14,666,268
- Analyst consensusNeutral
Financials of Arcellx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $107.9M | -$107.3M | -$132.4M |
| 2023 | $110.3M | -$70.7M | -$87.8M |
| 2022 | -$188.7M | -$189.0M | |
| 2021 | -$65.0M | -$64.0M |
Detailed financial statements for Arcellx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Arcellx
5 dated milestones of Arcellx across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Arcellx is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $100.0M.
- Exit Acquired by Gilead.
Competitors of Arcellx
Arcellx has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Arcellx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arcellx
The website of Arcellx (arcellx.com) receives about 14.9K visits a month and ranks #1,407,941 among all websites worldwide, #1,826 in Biotechnology and Pharmaceuticals.
- Monthly visits14.9K
▼ 21.7% vs previous month
- Unique visitors8.7K
per month
- Global rank#1,407,941
among all websites
- Category rank#1,826
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit31 sec
- DevicesDesktop 58% · Mobile 42%
Top companies in Cell Therapy
3 companies that operate in the same segment as Arcellx (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arcellx
Complete news archive for Arcellx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arcellx
Arcellx was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Arcellx is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Rami Elghandour is the CEO of Arcellx, as recorded in our data.
Arcellx is a funded company, having raised a total of $241.84M across 6 funding rounds to date.
Arcellx has 163 employees.
Annual revenue of Arcellx is $107.94M as on Dec 31, 2024.
Arcellx is engaged in the development of innovative cell therapies targeting cancer and autoimmune diseases. The company utilizes its proprietary D-Domain technology along with ddCAR and ARC-SparX platforms to enhance treatment approaches. Operating within the biotechnology sector, Arcellx aims to transform cancer treatment through scientific advancements and collaborative efforts. Its solutions are designed to prioritize patient care while challenging conventional methods in the fight against cancer.
Arcellx offers Cell Therapies and D-Domain Technology.
Yes, Arcellx is publicly traded on NASDAQ under the ticker symbol ACLX.
Arcellx has 24 investors. Key investors include Gilead, LG, Takeda Pharmaceuticals, Citadel, and Aju IB Investment.
Arcellx operates through Arcellx.